These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15640940)

  • 1. Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
    Knillová J; Bouchal J; Hlobilková A; Strnad M; Kolár Z
    Neoplasma; 2004; 51(5):358-67. PubMed ID: 15640940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
    Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
    Mad'arová J; Lukesová M; Hlobilková A; Strnad M; Vojtesek B; Lenobel R; Hajdúch M; Murray PG; Perera S; Kolár Z
    Mol Pathol; 2002 Aug; 55(4):227-34. PubMed ID: 12147712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
    Kokontis JM; Hay N; Liao S
    Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
    Colquhoun AJ; Venier NA; Vandersluis AD; Besla R; Sugar LM; Kiss A; Fleshner NE; Pollak M; Klotz LH; Venkateswaran V
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):346-52. PubMed ID: 22614062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines.
    Bouchal J; Baumforth KR; Sváchová M; Murray PG; von Angerer E; Kolár Z
    J Pharm Pharmacol; 2005 Jan; 57(1):83-92. PubMed ID: 15638997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.
    Rigas AC; Robson CN; Curtin NJ
    Oncogene; 2007 Dec; 26(55):7611-9. PubMed ID: 17599054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
    Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
    BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines.
    Katayama H; Murashima T; Saeki Y; Nishizawa Y
    Int J Oncol; 2010 Mar; 36(3):553-62. PubMed ID: 20126974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.
    Floyd MS; Teahan SJ; Fitzpatrick JM; Watson RW
    Prostate Cancer Prostatic Dis; 2009; 12(1):25-33. PubMed ID: 18475288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
    Lu K; Shih C; Teicher BA
    Cancer Chemother Pharmacol; 2000; 46(4):293-304. PubMed ID: 11052627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
    Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
    Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.